BiotechTube

Ublituximab + Lenalidomide

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkins Lymphoma

Conditions

Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia

Trial Timeline

Nov 21, 2012 → Feb 7, 2014

NCT ID
NCT01744912

About Ublituximab + Lenalidomide

Ublituximab + Lenalidomide is a phase 1 stage product being developed by TG Therapeutics for Non-Hodgkins Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01744912. Target conditions include Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

Hype Score Breakdown

Clinical
6
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01744912Phase 1Terminated

Competing Products

15 competing products in Non-Hodgkins Lymphoma

See all competitors
ProductCompanyStageHype Score
Acalabrutinib + ACP-319AstraZenecaPhase 1/2
32
JBH492NovartisPhase 1
21
Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2CRochePhase 1/2
36
Obinutuzumab + Glofitamab + Gemcitabine + OxaliplatinRochePhase 2
42
Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + RituximabAmgenPhase 2
35
hLL2 (epratuzumab)Gilead SciencesPhase 1
21
Velcade + TemsirolimusPfizerPhase 2
35
alemtuzumabSanofiPhase 1/2
24
Odronextamab + REGN5837Regeneron PharmaceuticalsPhase 1
36
Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + FludarabineBayerPhase 1/2
25
Rituximab + Fludarabine + CAMPTH-1HBayerPhase 2
32
Rituximab + CHOP + CVP + Ibritumomab TiuxetanBiogenPhase 2
32
Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y ZevalinBiogenPhase 2
32
UblituximabTG TherapeuticsPhase 1/2
29
XmAb13676XencorPhase 1
23